RT Journal Article
SR Electronic
T1 SARS-CoV-2 induces inflammasome-dependent pyroptosis and downmodulation of HLA-DR in human monocytes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.25.20182055
DO 10.1101/2020.08.25.20182055
A1 Ferreira, André C.
A1 Soares, Vinicius Cardoso
A1 de Azevedo-Quintanilha, Isaclaudia G.
A1 da Silva Gomes Dias, Suelen
A1 Fintelman-Rodrigues, Natalia
A1 Sacramento, Carolina Q.
A1 Mattos, Mayara
A1 de Freitas, Caroline S.
A1 Temerozo, Jairo R.
A1 Teixeira, Lívia
A1 Hottz, Eugenio Damaceno
A1 Barreto, Ester A
A1 Pão, Camila R. R.
A1 Palhinha, Lohanna
A1 Miranda, Milene
A1 Bou-Habib, Dumith Chequer
A1 Bozza, Fernando A.
A1 Bozza, Patrícia T.
A1 Souza, Thiago Moreno L.
YR 2020
UL http://medrxiv.org/content/early/2020/10/23/2020.08.25.20182055.abstract
AB Infection by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been associated with leukopenia and uncontrolled inflammatory response in critically ill patients. A better comprehension of SARS-CoV-2-induced monocyte death is essential for the identification of therapies capable to control the hyper-inflammation and reduce viral replication in patients with COVID-19. Here, we show that SARS-CoV-2 induces inflammasome activation and cell death by pyroptosis in human monocytes, experimentally infected and from patients under intensive care. Pyroptosis was dependent on caspase-1 engagement, prior to IL-1ß production and inflammatory cell death. Monocytes exposed to SARS-CoV-2 downregulate HLA-DR, suggesting a potential limitation to orchestrate the immune response. Our results originally describe mechanisms by which monocytes, a central cellular component recruited from peripheral blood to respiratory tract, succumb to control severe 2019 coronavirus disease (COVID-19).Author summary Since its emergence in China in late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused thousands of deaths worldwide. Currently, the number of individuals infected with SARS-CoV-2 and in need of antiviral, anti-inflammatory, anticoagulant and more invasive treatments has overwhelmed the health systems worldwide. In our study, we found that SARS-CoV-2 is capable of inducing inflammatory cell death in human monocytes, one of the main cell types responsible for anti-SARS-CoV-2 immune response. As a consequence of this intracellular inflammatory mechanism (inflammasome engagement), an exacerbated production of inflammatory mediators occurs. The infection also decreases the expression of HLA-DR in monocytes, a molecule related to the orchestration of the immune response in case of viral infections. We also demonstrated that the HIV-1 protease inhibitor, atazanavir (ATV), prevented the uncontrolled inflammatory response, cell death and reduction in HLA-DR expression in SARS-CoV-2-infected monocytes. Our study provides relevant information on the effects of SARS-CoV-2 infection on human monocytes, as well as on the effect of ATV in preventing these pathological effects on the host.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04468087Funding StatementStudy funded by the Carlos Chagas Filho Foundation for Research Support of the State of Rio de Janeiro - FAPERJ, National Research Council - CNPq. Oswaldo Cruz FoundationAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Comissao Nacional de etica em Pesquisa - CONEP 138 30650420.4.1001.0008)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data supporting the results of this study are available as supplementary files on the website mendeley.com